Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 8/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13936446 | 1.00 | GLP1R (0.49) | GLP1RC3AR1ALBFOLH1 | |
| SCHEMBL13936441 | 1.00 | GLP1R (0.49) | GLP1RC3AR1ALBFOLH1 | |
| SCHEMBL13936443 | 1.00 | GLP1R (0.49) | GLP1RC3AR1ALBFOLH1 | |
| SCHEMBL13936440 | 1.00 | GLP1R (0.49) | GLP1RC3AR1ALBFOLH1 | |
| SCHEMBL14547440 | 0.90 | GLP1R (0.42) | GLP1RC3AR1ALB | |
| SCHEMBL13498595 | 0.89 | GLP1R (0.41) | GLP1RC3AR1ALB | |
| SCHEMBL24630340 | 0.86 | GLP1R (0.49) | GLP1RALBFOLH1 | |
| SCHEMBL29072106 | 0.86 | GLP1R (0.49) | GLP1RALBFOLH1 | |
| SCHEMBL3485145 | 0.83 | GLP1R (0.50) | GLP1RALBFOLH1 | |
| SCHEMBL3485150 | 0.83 | GLP1R (0.50) | GLP1RALBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GLP1R 103/4885C3AR1 913/4885ALB 1237/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | GLP1R 14/4885C3AR1 3234/4885ALB 149/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | GLP1R 2352/4885C3AR1 959/4885ALB 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.